Olamkicept is under clinical development by Ferring International Center and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Olamkicept’s likelihood of approval (LoA) and phase transition for Ulcerative Colitis took place on 22 Oct 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Olamkicept Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Olamkicept overview
olamkicept (TJ-301) is under development for the treatment of inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis. The drug candidate is administered through intravenous route. The drug candidate is a recombinant soluble gp130 (sgp130) protein. It was also under development for rheumatoid arthritis (RA). It was also under development for the treatment of neuromyelitis optica, systemic sclerosis, castleman’s disease and system vasculitis
Ferring International Center overview
Ferring International Center (Ferring), a subsidiary of Ferring Holding SA research, develops and markets pharmaceutical products. The company offers products in the fields of reproductive health, endocrinology, gastroenterology, urology, and orthopedics. Its major products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; and Firmagon (degarelix) for prostate cancer. Its pipeline products encompass rHCG for Triggering FFM and rFSH for male infertility for infertility; FE 202767 for Lactation; RBX2660 enema for difficile infection among others. It has production facilities in Europe, Asia, and a manufacturing site in the US. Ferring is headquartered in Saint-Prex, Switzerland.
Quick View Olamkicept LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|